Fourth quarter 2025 – Impact of weak markets mitigated by cost improvements, sales agreement entered for Silicones division

Elkem reported Q4 2025 EBITDA of NOK 890m (down 24% YoY) and total operating income of NOK 7,284m (-14% YoY); group EPS was NOK (0.28) for the quarter and NOK (1.05) YTD, though EPS excluding the Silicones division would have been NOK 0.61 for 2025. The company entered a definitive agreement to sell the majority of its Silicones division to Bluestar, with the consideration settled by redemption of all 338,338,536 Bluestar-held Elkem shares, and the board proposes no dividend for 2025; balance sheet metrics include equity of NOK 24,026m (51% of assets), net interest-bearing debt NOK 11,883m (net debt/EBITDA 3.5x), cash NOK 3,806m and >NOK 6,000m undrawn lines. Segment detail: Silicon Products revenue NOK 3,231m (-14%) with EBITDA down 53% YoY; Carbon Solutions EBITDA NOK 174m (-38%); Silicones EBITDA NOK 399m (+6%); the release also flags trade/safeguard measures, subdued demand, and a fatal Silicones R&D accident in December 2025.

Analysis

Market structure: Elkem (ELK.OL) becomes a more cyclical metals/materials pure-play after the Silicones sale; winners are EU ferroalloy and silicon-metal producers (domestic EU producers benefit from safeguard-driven price recovery) and Bluestar in silicones if Chinese prices hold. Losers include downstream silicone-integrated customers and Elkem’s earnings diversification (Silicones removed), concentrating revenue volatility into Silicon Products and Carbon Solutions. Expect pricing power improvement for EU ferrosilicon over 3–12 months if safeguards persist, but silicon spot weakness keeps near-term margins under pressure.

Risk assessment: Key tail risks are regulatory rollback of safeguards (weeks–months), transaction failure or indemnity claims from the Lyon accident (legal/insurance losses potentially >NOK 500–1,000m), and an extended China demand slump that depresses silicones and silicon prices for 6–18 months. Immediate (days) market reaction will track sale close timelines and accident investigation headlines; short-term (0–6 months) risk is earnings guidance revisions; long-term (12–36 months) risk is higher earnings volatility due to loss of diversification. Watch NIBD/EBITDA moving above 4.0x or below 3.0x as a material credit/capital trigger.

Trade implications: Tactical idea—establish a small starter long in ELK.OL (2–3% NAV) with 6–12 month horizon anticipating a re-rate once Silicones divestment closes and EPS ex-Silicones (NOK ~0.61) is visible; hedge with a 6–9 month 25–30% OTM protective put or buy a call spread to cap premium. Pair trade: long EU ferroalloy/ferrosilicon exposure (e.g., Ferroglobe GPH.MC 1–2% NAV) vs short a silicone-intensive specialty chemical name if available, to capture relative recovery from EU safeguards. Fixed income: avoid buying ELK corporate debt until post-close leverage confirms below 3.0x.

Contrarian angles: Consensus focuses on near-term EBITDA decline; market may underprice the value of a simpler balance sheet and improved margin transparency post-sale—if sale reduces outstanding shares materially and removes Silicones volatility, ELK can rerate 20–40% over 12–24 months. Conversely, removing Silicones removes a division that was EBITDA-accretive (NOK ~399m q4) and the market may be underestimating longer-term cyclicality—use staged entries and size by leverage thresholds. Historical parallel: cyclical divestitures (e.g., commodity spin-offs) often compress near-term multiples but expand once cash returns and leverage improve within 12–18 months.

Key Decisions for Investors

• Establish a 2–3% NAV long position in Elkem (ELK.OL) within 1–4 weeks ahead of sale close; hedge with a 6–9 month protective put at ~25–30% OTM costing no more than 0.5% NAV, or buy a Jan 2027 call spread to cap premium if available.
• Add a 1–2% NAV long exposure to Ferroglobe (GPH.MC) or another EU ferrosilicon producer within 2 months to capture upside from safeguard-driven price improvement; trim if EU ferrosilicon reference prices fail to rise by +10% in 6 weeks.
• Do not increase exposure to Elkem credit or buy new ELK corporate bonds until reported NIBD/EBITDA falls below 3.0x post-close (monitor quarterly statement within 90 days); if below 3.0x, consider 3–4% NAV allocation to bond vs equity swap.
• Implement a pair trade: long ELK.OL (2% NAV) and short a silicone-integrated chemical peer (size 1–1.5% NAV) if Chinese silicone spot prices reverse and trade below current levels by >15% over 8 weeks—this isolates metals cyclicality vs silicone demand risk.
• Monitor three immediate catalysts over the next 30–90 days (sale completion date, EU safeguard enforcement updates, Lyon accident investigation findings). If sale completion is delayed >90 days or legal exposure guidance exceeds NOK 500m, reduce ELK equity exposure by 50% within 5 trading days.